Reading PRGO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PRGO free→Reading PRGO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PRGO free→NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-12
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is weak. Earnings quality is not assessable since the company is unprofitable. Management's recent track record has been unsteady, with frequent changes. Risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 53% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern occurs because it trades below peer multiples, but recent financials are weak. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $10.99. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $11 PRGO trades at 6× p/e, below its 13× p/e peer median. Our $23 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 53% below a flat-multiple fair value, below our forecast of about -2%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 55% of the time over the next year (vs 54% for the rest of the cohort, n=2391).
Over the trailing year it converted -0.10x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.36 → $0.36 (+0.0% / 30d). 0 raised, 3 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d. 40% of analysts rate Buy.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$215.
How much price usually moves either way.
On a bad day, this stock has moved -$426.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,556.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum rose by 23.7 points (from -11.1 to 12.6).
Signal changed from 'mixed' to 'mild_favorable'.
No material changes since the prior snapshot.
as of 2026-06-12
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show how well the company is doing and its trends.
Confirms one read:Earnings beat expectations with revenue growth over 5%.
Confirms the other:Earnings miss expectations with revenue growth below 0%.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PRGO yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Patrick Lockwood-Taylor On June 7, 2026, Patrick Lockwood-Taylor resigned, effective immediately, as President and Chief Executive Officer and as a member of the Board of Directors (the “Board”) of Perrigo Company plc (the “Company”). This resignation follows a determination by the Board that certain personal conduct was not consistent…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PRGO Perrigo | Above typical Show detailsSector percentile: 73 of 100 | inexpensive | elevated |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 85 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Typical Show detailsSector percentile: 69 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 62 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 62 of 100 | fair | low |
4 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-12.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-12.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on market share gains through the implementation of the Three-S plan.
Reaffirm full-year 2026 outlook with expectations for second-half improvement.
Use proceeds from divestitures, such as the Dermacosmetics business, to reduce debt.
Management aims to improve operating cash flow, which has been a recurring focus.
The company is committed to maintaining its dividend payments as part of its capital allocation strategy.
Why it matters: Improving cash flow shows Perrigo is managing costs better. This is key for growth.
Confirms:Operating cash flow improves year over year by more than 10%.
Disproves:Operating cash flow declines year over year or stays flat.
Why it matters: Maintaining the dividend shows commitment to shareholders. A cut could signal deeper issues.
Confirms:Perrigo maintains its dividend at $0.29 per share in Q2.
Disproves:Perrigo cuts the dividend below $0.29 per share.
Why it matters: Completing the acquisition may help Perrigo grow. It could also improve its market position.
Confirms:The acquisition closes on schedule and is confirmed in a press release.
Disproves:The acquisition is postponed or called off.
Results of Operations and Financial Condition On May 6, 2026, Perrigo Company plc (the “Company”) released earnings for the first quarter ended March 28, 2026. The press release related to the Company’s earnings is attached as Exhibit 99.1. The Company provides non-GAAP financial measures as additional information that it believes is useful to investors and analysts in evaluating the performance of the Company's ongoing operating trends, facilitating comparability between periods and, where a…
Completion of Acquisition of Disposition of Assets. As previously disclosed, on July 13, 2025, Perrigo Company plc (the “Company”) entered into a Master Sale and Purchase Agreement (the “Agreement”) with Kairos Bidco AB (“Kairos”), an affiliate of Karo Healthcare AB (“Karo”) and an investment vehicle managed by an affiliate of KKR & Co., Inc. (“KKR”), pursuant to which, and subject to the terms and conditions set forth therein, the Company agreed to sell and Karo agreed to acquire (1) all of…
and 7.01 of Form 8-K. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. (Registrant) PERRIGO COMPANY PLC By: /s/ Eduardo Bezerra Dated: April 22, 2026 Eduardo Bezerra Chief Financial Officer
of Form 8-K. 104 Cover Page Interactive Data file (embedded within the Inline XBRL document). * The Company has omitted certain schedules and other similar attachments to such agreement pursuant to Item 601(b) of Regulation S-K. The Company will furnish a copy of such omitted documents to the SEC upon request. † Pursuant to Item 601(b)(2)(ii) of Regulation S-K, certain portions of this exhibit have been redacted because the Company customarily and actually treats such omitted information as p…